PROM1 and cancer: CD133 is the most frequently studied CSC surface marker in many cancers, and specific antibodies/immunotoxins against CD133 have been successfully developed for the selective eradication of CSCs (Bach et al., 2013; Schmohl and Vallera, 2016).